[go: up one dir, main page]

ES2081102T3 - Vacuna para el herpes simple compuesta por glicoproteina gd del hsv y lipido a de monofosforilo 3-desacilado. - Google Patents

Vacuna para el herpes simple compuesta por glicoproteina gd del hsv y lipido a de monofosforilo 3-desacilado.

Info

Publication number
ES2081102T3
ES2081102T3 ES92906441T ES92906441T ES2081102T3 ES 2081102 T3 ES2081102 T3 ES 2081102T3 ES 92906441 T ES92906441 T ES 92906441T ES 92906441 T ES92906441 T ES 92906441T ES 2081102 T3 ES2081102 T3 ES 2081102T3
Authority
ES
Spain
Prior art keywords
hsv
monophosphorile
glycoprotein
lipid
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92906441T
Other languages
English (en)
Other versions
ES2081102T5 (es
Inventor
Myriam Francotte
Jean-Paul Prieels
Moncef Slaoui
Nathalie Marie- Garcon-Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10691946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2081102(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Application granted granted Critical
Publication of ES2081102T3 publication Critical patent/ES2081102T3/es
Publication of ES2081102T5 publication Critical patent/ES2081102T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE PRESENTAN NUEVAS FORMULACIONES PARA UNA VACUNA CONTRA EL VIRUS DEL HERPES SIMPLE (HSV). ESTAS CONTIENEN UNA GLICOPROTEINA GD DEL HSV O FRAGMENTOS INMUNOLOGICOS JUNTO CON UN LIPIDO A DE MONOFOSFORILO DESACILADO EN LA POSICION 3.
ES92906441T 1991-03-21 1992-03-17 Vacuna para el herpes simple compuesta por glicoproteina gd del hsv y lipido a de monofosforilo 3-desacilado. Expired - Lifetime ES2081102T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9105992A GB9105992D0 (en) 1991-03-21 1991-03-21 Vaccine

Publications (2)

Publication Number Publication Date
ES2081102T3 true ES2081102T3 (es) 1996-02-16
ES2081102T5 ES2081102T5 (es) 2001-09-01

Family

ID=10691946

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92906441T Expired - Lifetime ES2081102T5 (es) 1991-03-21 1992-03-17 Vacuna para el herpes simple compuesta por glicoproteina gd del hsv y lipido a de monofosforilo 3-desacilado.

Country Status (34)

Country Link
US (1) US6027730A (es)
EP (1) EP0576478B2 (es)
JP (1) JP3530526B2 (es)
KR (1) KR100224329B1 (es)
CN (2) CN1058191C (es)
AP (1) AP298A (es)
AT (1) ATE129160T1 (es)
AU (1) AU650521B2 (es)
BR (1) BR9205745A (es)
CA (1) CA2106492C (es)
CY (1) CY1936A (es)
CZ (1) CZ280505B6 (es)
DE (1) DE69205566T3 (es)
DK (1) DK0576478T4 (es)
ES (1) ES2081102T5 (es)
FI (1) FI107881B (es)
GB (1) GB9105992D0 (es)
GR (1) GR3017884T3 (es)
HK (1) HK1004525A1 (es)
HU (1) HU218025B (es)
IE (1) IE69560B1 (es)
IL (1) IL101290A (es)
MA (1) MA22471A1 (es)
MX (1) MX9201245A (es)
MY (1) MY110086A (es)
NO (1) NO307499B1 (es)
NZ (1) NZ242057A (es)
PL (1) PL170059B1 (es)
PT (1) PT100262B (es)
SA (1) SA92120459B1 (es)
SK (1) SK279190B6 (es)
WO (1) WO1992016231A1 (es)
YU (1) YU28392A (es)
ZA (1) ZA922011B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
GB9202933D0 (en) * 1992-02-12 1992-03-25 Smithkline Beecham Biolog Vaccines
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
EP0684838A1 (en) * 1993-02-19 1995-12-06 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
ATE204762T1 (de) * 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
EP0705109B2 (en) * 1993-05-25 2004-01-02 American Cyanamid Company Adjuvants for vaccines against respiratory syncytial virus
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5977315A (en) * 1994-12-28 1999-11-02 The Board Of Trustees Of The University Of Kentucky Murine anti-idiotype antibody 3H1
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US20020041872A1 (en) 1996-04-12 2002-04-11 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6235280B1 (en) 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6468782B1 (en) 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
US6274143B1 (en) 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
GB9819898D0 (en) * 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
EP1126876B1 (en) 1998-10-16 2007-03-21 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
US7026155B2 (en) 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
EP1104767A1 (en) 1999-11-30 2001-06-06 Stichting Dienst Landbouwkundig Onderzoek Mono- and disaccharide derivatives containing both fatty acid ester and sulfate ester groups
US9273326B2 (en) 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
CN101128215B (zh) 2004-09-22 2012-10-10 葛兰素史密丝克莱恩生物有限公司 用于进行抗葡萄球菌接种的免疫原性组合物
US20090081253A1 (en) 2005-03-23 2009-03-26 Glaxosmithkline Biologicals S.A. Composition
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP3470080A1 (en) 2005-12-22 2019-04-17 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
PH12013500136A1 (en) 2006-03-30 2015-03-13 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2008009309A1 (en) 2006-07-17 2008-01-24 Glaxosmithkline Biologicals S.A. Influenza vaccine
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8273361B2 (en) 2006-09-26 2012-09-25 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
AR066405A1 (es) 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa Vacuna
MX2009013949A (es) 2007-06-26 2010-05-24 Glaxosmithkline Biolog Sa Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae.
ES2732815T3 (es) 2009-05-22 2019-11-26 Genocea Biosciences Inc Vacunas frente al virus del herpes simple de tipo 2: composiciones y métodos para provocar una respuesta inmunitaria
TWI549688B (zh) * 2009-06-05 2016-09-21 美國疾病傳染研究機構 合成的葡萄吡喃糖基脂質佐劑
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
RS54933B1 (sr) 2009-12-21 2016-10-31 Brigham & Womens Hospital Inc Vakcine herpes simpleks virusa
CA2856697A1 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
CN108126204A (zh) * 2011-03-11 2018-06-08 特斯通有限责任合伙公司 包含组蛋白去乙酰化酶抑制剂的疫苗接种方法
SG194083A1 (en) 2011-04-08 2013-11-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EP3329936A1 (en) 2011-08-22 2018-06-06 Nanobio Corporation Herpes simplex virus nanoemulsion vaccine
JP6199878B2 (ja) 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
EP3388835B1 (en) 2012-05-16 2020-04-01 Immune Design Corp. Vaccines for hsv-2
ES2847930T3 (es) 2013-01-07 2021-08-04 Mucosal Vaccine Tech Llc Vacunas terapéuticas para el tratamiento de las infecciones por el virus del herpes simple de tipo 2
EP2986303B1 (en) 2013-04-18 2020-02-26 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US10350288B2 (en) 2016-09-28 2019-07-16 Genocea Biosciences, Inc. Methods and compositions for treating herpes
WO2019152821A1 (en) 2018-02-05 2019-08-08 The Brigham And Women's Hospital, Inc. Recombinant herpes simplex virus-2 expressing glycoprotein b and d antigens
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372945A (en) * 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4762708A (en) * 1982-02-18 1988-08-09 University Patents, Inc. Materials and methods for herpes simplex virus vaccination
US5149660A (en) * 1982-02-18 1992-09-22 University Patents, Inc. Diagnostic reagents relating to herpes simplex virus
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
EP0289550B1 (en) * 1986-10-20 1996-04-10 Chiron Corporation Vaccine for use in the therapeutic treatment of hsv
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ230424A (en) * 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen
ATE147633T1 (de) * 1988-10-27 1997-02-15 Univ Minnesota Immunhilfsmittel aus liposome enthaltend lymphokin il -2
US5597573A (en) * 1989-05-04 1997-01-28 Igen, Inc. Lipid-A analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
WO1991001146A1 (en) * 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
CA2088246A1 (en) * 1990-08-01 1992-02-02 Dennis J. O'callaghan Gene encoding equine herpesvirus type i glycoprotein d, its gene product, antibodies and their uses
DE69131200T2 (de) * 1990-08-02 1999-12-09 Chiron Corp., Emeryville Herpes simplex virus vp16 impfstoffe
GB9106048D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
US5196452A (en) * 1991-01-29 1993-03-23 Genelabs Incorporated Macrocyclic anti-viral compound and method
US5166173A (en) * 1991-01-29 1992-11-24 Genelabs Incorporated Method of treating herpes simplex virus infection
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
MY111880A (en) * 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
EP0671948B1 (en) * 1992-06-25 1997-08-13 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
EP0684838A1 (en) * 1993-02-19 1995-12-06 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
ATE204762T1 (de) * 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
EP0705109B2 (en) * 1993-05-25 2004-01-02 American Cyanamid Company Adjuvants for vaccines against respiratory syncytial virus

Also Published As

Publication number Publication date
MX9201245A (es) 1992-10-01
IE69560B1 (en) 1996-10-02
DE69205566T2 (de) 1996-04-18
PT100262A (pt) 1993-06-30
IL101290A (en) 1996-07-23
ES2081102T5 (es) 2001-09-01
MY110086A (en) 1997-12-31
CN1101226C (zh) 2003-02-12
DK0576478T4 (da) 2001-07-23
JPH06505727A (ja) 1994-06-30
SK94693A3 (en) 1994-05-11
PT100262B (pt) 2001-05-31
GB9105992D0 (en) 1991-05-08
FI934134A (fi) 1993-09-21
NO307499B1 (no) 2000-04-17
NO933343L (no) 1993-09-20
AU650521B2 (en) 1994-06-23
FI107881B (fi) 2001-10-31
FI934134A0 (fi) 1993-09-21
DK0576478T3 (da) 1995-12-04
EP0576478B2 (en) 2001-04-18
DE69205566T3 (de) 2002-09-05
EP0576478A1 (en) 1994-01-05
AP298A (en) 1994-01-14
MA22471A1 (fr) 1992-10-01
NZ242057A (en) 1993-12-23
BR9205745A (pt) 1994-10-18
EP0576478B1 (en) 1995-10-18
CN1065997A (zh) 1992-11-11
GR3017884T3 (en) 1996-01-31
AP9200368A0 (en) 1992-04-30
IL101290A0 (en) 1992-11-15
SA92120459B1 (ar) 2005-06-14
DE69205566D1 (en) 1995-11-23
PL170059B1 (pl) 1996-10-31
CY1936A (en) 1992-03-17
CA2106492A1 (en) 1992-09-22
HK1004525A1 (en) 1998-11-27
SK279190B6 (sk) 1998-07-08
CN1201692A (zh) 1998-12-16
YU28392A (sh) 1994-11-15
AU1365792A (en) 1992-10-21
CA2106492C (en) 2003-12-09
JP3530526B2 (ja) 2004-05-24
HU218025B (hu) 2000-05-28
NO933343D0 (no) 1993-09-20
HUT67052A (en) 1995-01-30
WO1992016231A1 (en) 1992-10-01
CZ195893A3 (en) 1994-07-13
CN1058191C (zh) 2000-11-08
CZ280505B6 (cs) 1996-02-14
HU9302645D0 (en) 1994-01-28
US6027730A (en) 2000-02-22
KR100224329B1 (ko) 1999-10-15
ZA922011B (en) 1993-01-27
ATE129160T1 (de) 1995-11-15
IE920881A1 (en) 1992-09-23

Similar Documents

Publication Publication Date Title
ES2081102T3 (es) Vacuna para el herpes simple compuesta por glicoproteina gd del hsv y lipido a de monofosforilo 3-desacilado.
ES2098029T3 (es) Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado.
FR2647808B1 (fr) Poxvirus recombinant et vaccin contre le virus de l'herpes contenant ce poxvirus
CO5210894A1 (es) Composiciones adyudantes que comprenden una sal de aluminio y un inmunoestimulante
ES2140076T3 (es) Vacunas que contienen una saponina y un esterol.
ES2179105T3 (es) Adyuvantes proteinicos.
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
ES2113882T3 (es) Vacuna oral que comprende un antigeno asociado superficialmente con eritrocitos.
ES2136088T3 (es) Compuestos inmunogenos con efecto principalmente anti-citoquina, procedimiento de preparacion, composiciones farmaceuticas y kits que los contienen.
ATE72123T1 (de) Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort.
ES2134197T3 (es) Vacunas contra el virus del herpes simplex vp16.
ATE118353T1 (de) Rekombinanter herpes simplex gb-gd impfstoff.
SE9600647D0 (sv) Ny användning
EP0716613A4 (en) TREATING A GASTRODUODENAL DISEASE CAUSED BY -i (HELICOBAKTER PYLORI)
FR2669346B1 (fr) Vaccin a poxvirus recombinant contre le virus de la rougeole.
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
ATE147271T1 (de) Azellulärer impfstoff
ES2187489T3 (es) Composiciones farmaceuticas a base de diclofenac.
AR010794A1 (es) Vacuna para la vacunacion in ovo de aves de corral contra la enfermedad newcastle y uso del virus de la enfermedad newcastle en la preparacion de dichavacuna
ES2079851T3 (es) Uso de il-4 para mejorar la respuesta inmunitaria frente a inmunogenos en vacunas.
ES2057008T3 (es) Medicamento.
MX9303771A (es) Proteina viral icp27 del virus vhs-2, proceso para su preparacion y composicion de vacuna que la incluye.
AR241574A1 (es) Procedimiento para preparar una nueva composicion farmaceutica para tratar la insuficiencia cardiaca.
ES2074965B1 (es) Virus mutante recombinante de rinotraqueitis infecciosa bovina y vacunas que lo contienen.
FR2698271B1 (fr) Vaccin contre le virus de la leucémie bovine, nouveau peptide immunogène et kit de vaccination.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 576478

Country of ref document: ES